Prostate and Neuroendocrine Tumours: Workshop on New Methods of Diagnosis and Therapeutics

Tumores da próstata e tumores neuroendócrinos: workshop sobre novos métodos de diagnóstico e terapêutica

Hospital da Luz will hold, next May 19, a workshop on new methods of diagnosis and therapeutics (“Theranostics”) in prostate and neuroendocrine tumours.

This eminently practical course is organized by Rosário Vieira (the coordinator of Hospital da Luz Lisboa Molecular Medicine Service) and is destined to specialist physicians, interns, technicians and nurses working in the areas of Nuclear Medicine, Oncology, Endocrinology, General Surgery, Urology and Radiotherapy.

The term “theranostic” is used to designate the combination of diagnostic and tumoral therapeutic techniques: obtaining full body images with PET-CT equipment and using specific radiopharmaceuticals to study a particular organ or system or a particular pathology, the best therapy to treat that “specific tumoral pathology” is identified, materialising Ehrlich’s principle of the “magic bullet”.

In fact, through these imaging techniques and using molecules as radioactive markers, specialists in nuclear medicine characterize and quantify the biological processes occurring at cellular and molecular level in the human body – that is to say, they mark the affected cells in the areas of the body with the disease. And the new molecules can be marked with radionuclides, whose emission spectrum has therapeutic effect in the targeted cells.

“In this workshop, we propose to improve communication between the different areas of knowledge implicated and ensure the scientific community access to new therapeutic modalities, always in view of the most adequate treatment and higher survival rate for these patients”, stresses Rosário Vieira.

In what concerns prostate tumours, “the goal is to try to reach a consensus on the imaging techniques to employ”.

In the program dedicated to neuroendocrine tumours, clinical cases and topics will be approached, such as the heterogeneity of these tumours, where identification and demonstration through imaging is determinant to apply efficient therapeutics, reflecting the practical advantages of personalized medicine.

In the part of the program dedicated to advanced prostate carcinoma therapeutics, highlight goes to Thomas Langbein, from Zentralklinic Bad Berka, in Germany, who will approach the practical demonstration in this area of knowledge on the concept of “theranostics”.

The workshop panel of speakers counts with highly experienced specialists from Hospital da Luz Lisboa, Hospital Beatriz Ângelo, British Hospital, Oncology Institutes from Coimbra, Lisbon and Oporto, Centro Hospitalar from Universidade de Coimbra and Centro Hospitalar Lisboa Norte, among others.

For more ore information and enrolment in the “Theranostics Workshop on prostate and neuroendocrine tumours”, click here.